Evidence map›Paper›PMID 38611590›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Incidental Prostate Cancer in Patients Treated for Benign Prostatic Hyperplasia: Analysis from a Contemporary National Dataset.

Eugenio Bologna, Leslie Claire Licari, Antonio Franco, Francesco Ditonno, Celeste Manfredi, Cosimo De Nunzio, Alessandro Antonelli, Marco De Sio, Costantino Leonardo, Giuseppe Simone and 2 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Eugenio BolognaDepartment of Maternal-Child and Urological Sciences, Sapienza University Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy.ORCID 0000-0002-1140-0590
Leslie Claire LicariDepartment of Maternal-Child and Urological Sciences, Sapienza University Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy.ORCID 0000-0002-3274-1247
Antonio FrancoDepartment of Urology, Rush University, Chicago, IL 60612, USA.
Francesco DitonnoDepartment of Urology, Rush University, Chicago, IL 60612, USA.ORCID 0009-0005-0126-4731
Celeste ManfrediDepartment of Urology, Rush University, Chicago, IL 60612, USA.ORCID 0000-0002-9706-8516
Cosimo De NunzioDepartment of Urology, Sant'Andrea Hospital, Sapienza University, 00189 Rome, Italy.
Alessandro AntonelliDepartment of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, 37129 Verona, Italy.ORCID 0000-0002-7455-8803
Marco De SioUnit of Urology, Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
Costantino LeonardoDepartment of Urology, "Regina Elena" National Cancer Institute, 00144 Rome, Italy.
Giuseppe SimoneDepartment of Urology, "Regina Elena" National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-4868-9025
Edward E CherulloDepartment of Urology, Rush University, Chicago, IL 60612, USA.
Riccardo AutorinoDepartment of Urology, Rush University, Chicago, IL 60612, USA.ORCID 0000-0001-7045-7725
Azienda Ospedaliera Sant'Andrea · ITPoliclinico Umberto I · ITRush University · USUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Prostate Cancer (PCa) may be incidentally diagnosed during the microscopic evaluation of resected tissue from BPH surgeries, characterizing the clinical condition known as incidental PCa (iPCa). This study aims to assess the prevalence of iPCa following BPH surgery to evaluate the associated surgical procedures and to scrutinize preoperative and postoperative management. (2) Methods: A retrospective analysis was conducted using the PearlDiver™ Mariner database, containing patient records compiled between 2011 and 2021. International Classification of Diseases (ICD) and Current Procedural Terminology (CPT) codes were employed to identify the population and outcomes. Our primary objective was to assess the prevalence of iPCa, categorized by the type of procedures, and to evaluate the subsequent treatment strategies. The secondary aim was to assess the impact of prostate biopsy (PB) and prostate MRI on iPCa detection. (3) Results: The overall cohort, accounting for 231,626 patients who underwent BPH surgery, exhibited a 2.2% prevalence rate of iPCa. The highest rate was observed for TURP (2.32%), while the lowest was recorded for RASP (1.18%). Preoperative MRI and PB demonstrated opposing trends over the years. Of the 5090 patients identified with iPCa, nearly 68% did not receive active treatment. The most common treatments were RT and ADT; 34.6% underwent RT, 31.75% received ADT, and 21.75% were treated with RT+ADT. RP was administered to approximately 9% of patients undergoing endoscopic procedures. Multivariate logistic regression analysis revealed age and openSP as additional risk factors for iPCa. Conversely, PB and MRI before surgery were linked to a decreased risk. (4) Conclusions: The contemporary prevalence of iPCa after BPH surgery is <3%. The increase in the use of prostate MRI mirrors a decline in the PB biopsy prior to BPH surgery but without resulting in an increased detection rate of iPCa. In contemporary routine clinical practice, iPCa is mostly managed in a different way when compared to biopsy-detected PCa.

Indexed as

BPHincidentalMRIprostate biopsyprostate cancer

Identifiers

PMID38611590
PMCPMC11011333
OpenAlexW4393141888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.